端粒酶
端粒酶逆转录酶
CTL公司*
生物
癌症
癌症免疫疗法
癌症研究
细胞毒性T细胞
免疫疗法
抗原
免疫学
体外
遗传学
CD8型
基因
出处
期刊:Oncogene
[Springer Nature]
日期:2002-01-21
卷期号:21 (4): 674-679
被引量:145
标识
DOI:10.1038/sj.onc.1205074
摘要
Although the search for pharmacologic inhibitors of telomerase activity represents a promising approach for telomerase-based anti-cancer therapy, the immunological properties of the telomerase reverse transcriptase hTERT suggest that the enzyme is also an attractive target for novel immunotherapies against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lymphocytes (CTL) can recognize peptides derived from TERT and kill TERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI